Ontology type: schema:ScholarlyArticle Open Access: True
2022-04-14
AUTHORSS. R. Aravind, Kiran P. Singh, Grace Aquitania, Liliia Mogylnytska, Alsu G. Zalevskaya, Beata Matyjaszek-Matuszek, Karin Wernicke-Panten, My-Liên Nguyên-Pascal, Suzanne Pierre, Baerbel Rotthaeuser, Daniel Kramer, Bhaswati Mukherjee
ABSTRACTIntroductionThis study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix 70/30 (SARAsp-Mix) with European-approved insulin aspart mix 70/30 − NovoMix® 30 (NN-Mix) in people with type 1 (T1D) or type 2 diabetes (T2D).MethodsThis 26-week, open-label, phase 3 trial enrolled 402 people with T1D (n = 105) or T2D (n = 297) previously treated with premix insulin, who were randomized (1:1) to SARAsp-Mix (n = 204) or NN-Mix (n = 198).ResultsAfter 26 weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARAsp-Mix − 0.55% [− 0.60%]; NN-Mix − 0.64% [− 0.60%]). The LS mean difference for SARAsp-Mix versus NN-Mix was 0.08%, with the upper bound of the two-sided 95% confidence interval (− 0.139 to 0.303) slightly above the prespecified noninferiority margin of 0.3%. Noninferiority of SARAsp-Mix over NN-Mix was not demonstrated in the primary intent-to-treat analysis, primarily because of one extreme outlying value impacted by the COVID-19 pandemic in the SARAsp-Mix group. Noninferiority was achieved in all secondary analyses, including prespecified per-protocol supportive and COVID-19 sensitivity analyses, as well as post hoc sensitivity analyses. Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia, and adverse events were similar between groups.ConclusionsThe totality of evidence indicates that SARAsp-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26 weeks.Trial RegistrationEudraCT number 2017-000092-84. More... »
PAGES1053-1071
http://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7
DOIhttp://dx.doi.org/10.1007/s13300-022-01255-7
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1147105305
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/35420397
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Columbia Asia Hospital, Bangalore, India",
"id": "http://www.grid.ac/institutes/grid.492708.0",
"name": [
"Diabetes Care and Research Center, Diacon Hospital, Bangalore, India",
"Columbia Asia Hospital, Bangalore, India"
],
"type": "Organization"
},
"familyName": "Aravind",
"givenName": "S. R.",
"id": "sg:person.01156425431.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156425431.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India",
"id": "http://www.grid.ac/institutes/grid.414986.6",
"name": [
"Department of Endocrinology, Fortis Hospital Mohali, Chandigarh, India"
],
"type": "Organization"
},
"familyName": "Singh",
"givenName": "Kiran P.",
"id": "sg:person.016302536424.88",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016302536424.88"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Davao Doctors Hospital, Davao City, Philippines",
"id": "http://www.grid.ac/institutes/grid.461105.7",
"name": [
"Davao Doctors Hospital, Davao City, Philippines"
],
"type": "Organization"
},
"familyName": "Aquitania",
"givenName": "Grace",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Khmelnytskyi Regional Hospital, Khmelnytskyi, Ukraine"
],
"type": "Organization"
},
"familyName": "Mogylnytska",
"givenName": "Liliia",
"id": "sg:person.012202624556.78",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012202624556.78"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia",
"id": "http://www.grid.ac/institutes/grid.412460.5",
"name": [
"Department of Endocrinology, First Pavlov State Medical University, St. Petersburg, Russia"
],
"type": "Organization"
},
"familyName": "Zalevskaya",
"givenName": "Alsu G.",
"id": "sg:person.011273171321.30",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011273171321.30"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Endocrinology, Medical University of Lublin, Lublin, Poland",
"id": "http://www.grid.ac/institutes/grid.411484.c",
"name": [
"Department of Endocrinology, Medical University of Lublin, Lublin, Poland"
],
"type": "Organization"
},
"familyName": "Matyjaszek-Matuszek",
"givenName": "Beata",
"id": "sg:person.01073771325.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01073771325.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany",
"id": "http://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
],
"type": "Organization"
},
"familyName": "Wernicke-Panten",
"givenName": "Karin",
"id": "sg:person.01241414567.61",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241414567.61"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi-Aventis Research and Development, Chilly-Mazarin, France",
"id": "http://www.grid.ac/institutes/grid.417924.d",
"name": [
"Sanofi-Aventis Research and Development, Chilly-Mazarin, France"
],
"type": "Organization"
},
"familyName": "Nguy\u00ean-Pascal",
"givenName": "My-Li\u00ean",
"id": "sg:person.014010762573.15",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014010762573.15"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi-Aventis Research and Development, Chilly-Mazarin, France",
"id": "http://www.grid.ac/institutes/grid.417924.d",
"name": [
"Sanofi-Aventis Research and Development, Chilly-Mazarin, France"
],
"type": "Organization"
},
"familyName": "Pierre",
"givenName": "Suzanne",
"id": "sg:person.016202073064.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016202073064.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany",
"id": "http://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
],
"type": "Organization"
},
"familyName": "Rotthaeuser",
"givenName": "Baerbel",
"id": "sg:person.016162055375.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016162055375.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany",
"id": "http://www.grid.ac/institutes/grid.420214.1",
"name": [
"Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany"
],
"type": "Organization"
},
"familyName": "Kramer",
"givenName": "Daniel",
"id": "sg:person.01154142027.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154142027.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Sanofi, 54 Rue La Bo\u00e9tie, 75008, Paris, France",
"id": "http://www.grid.ac/institutes/grid.417924.d",
"name": [
"Sanofi, 54 Rue La Bo\u00e9tie, 75008, Paris, France"
],
"type": "Organization"
},
"familyName": "Mukherjee",
"givenName": "Bhaswati",
"id": "sg:person.014750372124.55",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014750372124.55"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1208/s12248-014-9599-2",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1008471779",
"https://doi.org/10.1208/s12248-014-9599-2"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s40268-018-0228-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1101140162",
"https://doi.org/10.1007/s40268-018-0228-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.2165/11635490-000000000-00000",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1014783629",
"https://doi.org/10.2165/11635490-000000000-00000"
],
"type": "CreativeWork"
}
],
"datePublished": "2022-04-14",
"datePublishedReg": "2022-04-14",
"description": "IntroductionThis study compared the efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 Mix\u00a070/30 (SARAsp-Mix) with European-approved insulin aspart mix\u00a070/30\u2009\u2212\u2009NovoMix\u00ae 30 (NN-Mix) in people with type\u00a01 (T1D) or type\u00a02 diabetes (T2D).MethodsThis 26-week, open-label, phase\u00a03 trial enrolled 402 people with T1D (n\u2009=\u2009105) or T2D (n\u2009=\u2009297) previously treated with premix insulin, who were randomized (1:1) to SARAsp-Mix (n\u2009=\u2009204) or NN-Mix (n\u2009=\u2009198).ResultsAfter 26\u00a0weeks, the least squares (LS) mean [median] change in HbA1c from baseline was similar in both treatment groups (SARAsp-Mix\u2009\u2212\u20090.55% [\u2212\u20090.60%]; NN-Mix\u2009\u2212\u20090.64% [\u2212\u20090.60%]). The LS mean difference for SARAsp-Mix versus NN-Mix was 0.08%, with the upper bound of the two-sided 95% confidence interval (\u2212\u20090.139 to 0.303) slightly above the prespecified noninferiority margin of 0.3%. Noninferiority of SARAsp-Mix over NN-Mix was not demonstrated in the primary intent-to-treat analysis, primarily because of one extreme outlying value impacted by the COVID-19 pandemic in the SARAsp-Mix group. Noninferiority was achieved in all secondary analyses, including prespecified per-protocol supportive and COVID-19 sensitivity analyses, as well as post hoc sensitivity analyses. Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia, and adverse events were similar between groups.ConclusionsThe totality of evidence indicates that SARAsp-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26\u00a0weeks.Trial RegistrationEudraCT number 2017-000092-84.",
"genre": "article",
"id": "sg:pub.10.1007/s13300-022-01255-7",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1044057",
"issn": [
"1869-6953",
"1869-6961"
],
"name": "Diabetes Therapy",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "13"
}
],
"keywords": [
"prespecified noninferiority margin",
"open-label trial",
"effective glycemic control",
"premix insulin",
"efficacy endpoint",
"treat analysis",
"adverse events",
"glycemic control",
"similar safety",
"immunogenicity profile",
"antibody response",
"noninferiority margin",
"insulin dosage",
"IntroductionThis study",
"treatment groups",
"secondary analysis",
"diabetes",
"confidence intervals",
"noninferiority",
"COVID-19 pandemic",
"trials",
"weeks",
"group",
"safety",
"HbA1c",
"MethodsThis",
"Randomized",
"T2D",
"hypoglycemia",
"T1D",
"NovoMix",
"primary intent",
"immunogenicity",
"insulin",
"baseline",
"endpoint",
"efficacy",
"people",
"sensitivity analysis",
"dosage",
"pandemic",
"response",
"interval",
"evidence",
"differences",
"analysis",
"control",
"study",
"protocol",
"intent",
"events",
"post",
"profile",
"changes",
"outlying values",
"margin",
"types",
"Europeans",
"values",
"mix",
"phase",
"totality",
"least squares",
"squares"
],
"name": "Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)",
"pagination": "1053-1071",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1147105305"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s13300-022-01255-7"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"35420397"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s13300-022-01255-7",
"https://app.dimensions.ai/details/publication/pub.1147105305"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:12",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_942.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s13300-022-01255-7"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-022-01255-7'
This table displays all metadata directly associated to this object as RDF triples.
237 TRIPLES
21 PREDICATES
92 URIs
81 LITERALS
7 BLANK NODES